Asian shares sink after losses for Big Tech pull US stocks lower

Market Overview - Tokyo's Nikkei 225 index fell over 4% amid a broader decline in Asian markets following a retreat on Wall Street, primarily driven by selling in Big Tech shares [1] - The Nikkei index was down 2.8% by mid-afternoon, closing at 50,090.33 [1] Company Performance - SoftBank Group's shares dropped 9.8% due to concerns over its investments in artificial intelligence [2] - Tokyo Electron and Advantest Corp. saw declines of 4.1% and 7.2% respectively, reflecting negative sentiment in the tech sector [2] - Palantir Technologies fell 7.9% despite beating analysts' forecasts, indicating market volatility [5] - Nvidia and Microsoft also experienced declines of 4% and 0.5% respectively, contributing to the overall downturn in the tech sector [5] - Uber's stock slumped 5.1% despite reporting better-than-expected financial results, highlighting a disconnect between earnings and stock performance [6] Sector Analysis - The technology sector, which has been a significant driver of market gains this year, is facing pressure due to heavy selling on Wall Street [3] - The S&P 500 index fell 1.2% to 6,771.55, although it remains up over 15% for the year [5] - The Dow Jones Industrial Average decreased by 0.5% to 47,085.24, while the Nasdaq fell 2% to 23,348.64, indicating a broader market trend [6] Economic Context - The upcoming financial results from major companies like McDonald's, Expedia Group, and Qualcomm are expected to be significant for market direction amid a US government shutdown [7] - Consumer prices rose 3% in September, the highest increase since January, complicating the Federal Reserve's interest rate policy decisions [8] Other Notable Movements - Tesla's shares fell 5.1% after Norway's sovereign wealth fund announced it would vote against a proposed compensation package for CEO Elon Musk [9] - Yum Brands' stock jumped 7.3% following news of a potential sale of its struggling Pizza Hut unit [10] - Novo Nordisk's shares slipped 1.8% after raising its offer to acquire Metsera, which surged 20.5% amid a bidding war with Pfizer, which fell 1.5% [10]